Product Information
TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE) is a generic product labeled by Jubilant Cadista Pharmaceuticals Inc., priced at $0.6881 per EA under NDC 59746080001. Its NADAC has been published 56 times since Sep 10, 2025.
FDA first approved this application on Sep 28, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
Jubilant Cadista Pharmaceuticals Inc.NDC
59746080001
Classification
Generic
Dosage Form
CAPSULE, GELATIN COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TACROLIMUSApproval Type
Generic (ANDA)
FDA Application
ANDA090802FDA Approved
9/28/2012
TE Code
AB
On Market Since
11/30/2024
Pharmacological Classes
Price Statistics
The NADAC for TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE) has been published 56 times since Sep 10, 2025, and over the history we have for it it has declined 20.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6881 per EA |
|---|---|
| All-time high | $0.8637 (Sep 10, 2025) |
| All-time low | $0.6505 (Jun 17, 2026) |
| 52-week high | $0.8265 |
| 52-week low | $0.6505 |
| Median price | $0.7030 |
| Average price | $0.7256 |
| Largest weekly change | -5.3% (Jan 21, 2026) |
| Weeks tracked | 56 |
| Tracking since | Sep 10, 2025 |
Generic Alternatives
The matcher finds 12 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 2% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Jubilant Cadista Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Tacrolimus market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcineurin Inhibitor Immunosuppressant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE)?
The current National Average Drug Acquisition Cost (NADAC) for TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE), manufactured by Jubilant Cadista Pharmaceuticals Inc., is $0.6881 per EA (NDC 59746080001), effective Sep 30, 2026.
How has the price of TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE) changed over time?
Over the history we have for it, the NADAC for TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE) has declined 20.3%. It has been tracked across 56 weekly CMS publications since Sep 10, 2025.
What are the highest and lowest recorded NADAC prices for TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE)?
Since Sep 10, 2025, the NADAC for TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE) has ranged from a low of $0.6505 (Jun 17, 2026) to a high of $0.8637 (Sep 10, 2025), with a median of $0.7030 per EA.
Are there cheaper alternatives to TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE)?
Yes. 12 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE), is $0.6746 per EA — about 2% below TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE).
Who manufactures TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE)?
TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE) (NDC 59746080001) is labeled by Jubilant Cadista Pharmaceuticals Inc., and CMS classifies it as a generic product.